Perspective Therapeutics/CATX

-1.25%
-
1D1W1MYTD1YMAX

About Perspective Therapeutics

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Ticker

CATX

Sector

Healthcare

Trading on

AMEX

Industry

Medical Equipment & Supplies

CEO

Lori Woods

Employees

116

Headquarters

Seattle, United States
Website
isoray.com

CATX Metrics

BasicAdvanced
US$940M
Market cap
-
P/E ratio
-US$0.20
EPS
1.45
Beta
-
Dividend rate
US$940M
1.45306
US$1.91
US$0.21
5.1M
-103.74%
-139.02%

What the Analysts think about CATX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
43.04% upside
High US$3.00
Low US$1.70
US$1.58
Current price
US$2.26
Average price target

CATX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-4,066.66% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$300K
-78.57%
Net income
-US$12M
-73.76%
Profit margin
-4,066.66%
22.44%

CATX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.28%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.02
-US$0.04
-US$0.09
-US$0.02
-
Expected
-US$0.01
-US$0.04
-US$0.04
-US$0.02
-US$0.02
Surprise
100%
0%
140%
-14.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Perspective Therapeutics stock?

Perspective Therapeutics (CATX) has a market cap of $940M as of May 20, 2024.

What is the P/E ratio for Perspective Therapeutics stock?

The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of May 20, 2024.

Does Perspective Therapeutics stock pay dividends?

No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Perspective Therapeutics dividend payment date?

Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.

What is the beta indicator for Perspective Therapeutics?

Perspective Therapeutics (CATX) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Perspective Therapeutics stock price target?

The target price for Perspective Therapeutics (CATX) stock is $2.26, which is 38.65% above the current price of $1.63. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Perspective Therapeutics stock

Buy or sell Perspective Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing